Altamira Therapeutics Announces Launch of Bentrio in Hong Kong by its Partner Nuance Pharma
30 Noviembre 2022 - 7:07AM
- Initiative is Nuance’s first step in penetrating Chinese market
with BentrioTM
- Densely populated Hong Kong (7.3 million) remains negatively
impacted by COVID-19
- Nuance Pharma to file for marketing approval in Macao, Mainland
China and South Korea in 2023
Altamira Therapeutics Ltd. (NASDAQ: CYTO), a company dedicated
to developing therapeutics that address important unmet medical
needs, today announced that its licensee and distribution
partner Nuance Pharma has launched its Bentrio nasal spray in Hong
Kong.
Bentrio is being marketed in Hong Kong to help with protection
against both airborne viruses as well as allergens. Hong Kong has a
population of about 7.3 million people that lives in an area of
just 1,104 square kilometers making it one of the most densely
populated places in the world.
Earlier this year, the Company entered into an exclusive Bentrio
license and distribution agreement with Nuance covering Mainland
China, Hong Kong, Macao and South Korea that included an upfront
payment made to Altamira of $1 million, plus future development and
commercial milestones of up to $3 million, and up to $19.5 million,
respectively. Upon reaching certain milestones, Nuance will assume
local production of Bentrio for its licensed territory and pay to
Altamira a staggered royalty at a high-single to low-double digit
percentage.
“We are very excited to see our partner Nuance Pharma take the
first step in bringing Bentrio to the promising Chinese market,”
commented Thomas Meyer, Altamira’s founder, Chairman and CEO.
“Daily life in Hong Kong continues to be negatively impacted by
COVID-19. We believe that Bentrio, with its triple mode of action,
offers a safe and effective means to strengthen protection against
harmful airborne particles. We look forward to working together
with Nuance Pharma in requesting marketing approval for Bentrio in
Macao, Mainland China and South Korea in 2023.”
About Nuance PharmaNuance Pharma is a
patient-centric and innovation focused biopharmaceutical company,
with both clinical and commercial stage assets. Founded by Mark
Lotter in 2014, with the mission to address critical unmet medical
needs in Greater China and Asia Pacific, Nuance has built a late
clinical stage innovative portfolio, while maintaining a
self-sustainable commercial operation. Focusing on specialty care,
Nuance's portfolio represents a differentiated combination of
commercial stage and innovative pipeline assets across respiratory,
emergency care, and iron deficiency anemia. For more information,
visit: https://www.nuancepharma.com/
About Bentrio™AM-301, marketed as Bentrio™, is a
drug-free nasal spray for personal protection against airborne
viruses and allergens. Upon application into the nose, Bentrio™
forms a protective gel layer on the nasal mucosa. This thin film is
designed to prevent the contact of viruses or allergens with cells;
in addition, the composition serves to bind such particles and help
with their discharge and to humidify the nasal mucosa. Together,
this is designed to reduce the risk of upper respiratory tract
viral infections and promote alleviation of allergic symptoms. For
more info,
visit: https://altamiratherapeutics.com/our-products/bentrio.
Bentrio™ is being distributed in selected European countries and
is expected to become available through distributors in further
countries in Europe, Asia and MENA. In the US, Altamira submitted a
510(k) application of Bentrio™ in the treatment of allergic
rhinitis, which is currently under review by the FDA.
About Altamira Therapeutics Altamira Therapeutics
(NASDAQ:CYTO) is dedicated to developing therapeutics that address
important unmet medical needs. The Company is currently active in
three areas: the development of RNA therapeutics for extrahepatic
therapeutic targets (OligoPhore™ / SemaPhore™ platforms;
preclinical stage), nasal sprays for protection against airborne
allergens and, where approved, viruses (Bentrio™; commercial) or
for the treatment of vertigo (AM-125; post Phase 2), and the
development of therapeutics for intratympanic treatment of tinnitus
or hearing loss (Keyzilen® and Sonsuvi®; Phase 3). Founded in 2003,
it is headquartered in Hamilton, Bermuda, with its main operations
in Basel, Switzerland. For more information,
visit: https://altamiratherapeutics.com/
Forward-Looking Statements This press release may contain
statements that constitute "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. Forward-looking
statements are statements other than historical facts and may
include statements that address future operating, financial or
business performance or Altamira Therapeutics' strategies or
expectations. In some cases, you can identify these statements by
forward-looking words such as "may", "might", "will", "should",
"expects", "plans", "anticipates", "believes", "estimates",
"predicts", "projects", "potential", "outlook" or "continue", or
the negative of these terms or other comparable terminology.
Forward-looking statements are based on management's current
expectations and beliefs and involve significant risks and
uncertainties that could cause actual results, developments and
business decisions to differ materially from those contemplated by
these statements. These risks and uncertainties include, but are
not limited to, the effect of the reverse split on Altamira’s stock
price and compliance with Nasdaq listing requirements, the closing
of the initial sale of Zilentin, the exercise by Zilentin of its
option to purchase additional legacy assets, the achievement by
Altamira of the milestones set forth in the option agreement,
Altamira’s ability to complete a divestiture transaction of
Bentrio, Altamira Therapeutics' need for and ability to raise
substantial additional funding to continue the development of its
product candidates, the timing and conduct of clinical trials of
Altamira Therapeutics' product candidates, the clinical utility of
Altamira Therapeutics' product candidates, the timing or likelihood
of regulatory filings and approvals, Altamira Therapeutics'
intellectual property position and Altamira Therapeutics' financial
position, including the impact of any future acquisitions,
dispositions, partnerships, license transactions or changes to
Altamira Therapeutics' capital structure, including future
securities offerings. These risks and uncertainties also include,
but are not limited to, those described under the caption "Risk
Factors" in Altamira Therapeutics' Report on Form 6-K for the six
months ended June 30, 2022, and in Altamira Therapeutics' other
filings with the SEC, which are available free of charge on the
Securities Exchange Commission's website at: www.sec.gov Should one
or more of these risks or uncertainties materialize, or should
underlying assumptions prove incorrect, actual results may vary
materially from those indicated. All forward-looking statements and
all subsequent written and oral forward-looking statements
attributable to Altamira Therapeutics or to persons acting on
behalf of Altamira Therapeutics are expressly qualified in their
entirety by reference to these risks and uncertainties. You should
not place undue reliance on forward-looking statements.
Forward-looking statements speak only as of the date they are made,
and Altamira Therapeutics does not undertake any obligation to
update them in light of new information, future developments or
otherwise, except as may be required under applicable law.
Investor Contacts
Investors@altamiratherapeutics.com
800-460-0183
Altamira Therapeutics (NASDAQ:CYTO)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
Altamira Therapeutics (NASDAQ:CYTO)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025
